Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexo...
How might the trial progress and revenue trends influence short‑term technical indicators and trading volume for KPTX?
What is the expected timeline for any potential regulatory submissions or approvals related to selinexor following the trial outcomes?
How does Karyopharm's total revenue of $37.9 million compare with consensus estimates for Q2 2025?
27 days ago